Staff
2 employees on 31-12-2025
In 2025, 1 person joined and 2 left.
Mega Pharma
Lifetime
14 annual accounts with figures on one time axispeak €164,640 (2024)
€130,361▼ 20.8%
lowest -€30,878 (2025)
-€30,878▼ €38,752
peak €183,451 (2022)
€131,985▼ 19.0%
€238,710▼ 7.0%
peak 1.2 FTE (2021)
-not published
Board1 name since 2021
1 director
Documentsfilings and deeds
29-07-20262 days before the deadline
2025micro format
Gross margin from €164,640 to €130,361Loss of €30,878Equity from €162,863 to €131,985Cash from €53,128 to €91,689
Key points
from the 2025 annual accountsFilings
14 annual accounts since 2012
The last five annual accounts were filed 2 to 55 days before the end of the period.
Position in the sector
-€30,878
Lower net result than 92% of companies in retail trade. Sector median €4,763 · 25,208 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 6,908 companies had the same profile as Mega Pharma has now. Each dot stands for 18 companies, two years later.
90.9%
were still trading
7.8%
stopped another way
1.1%
went bankrupt
Another 0.2% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,331 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 6,908 companies, not a prediction for Mega Pharma. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0840972479
Change of role: , from manager to director
Director discharge: · General meeting of 15-12-2023 · Gazette deed
First establishment
Leopold II laan 75, Molenbeek-Saint-Jean
Incorporation
published on 23-11-2011 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| Mega Pharma Molenbeek-Saint-Jean | €370,696 | €130,361 | 35.6% | - |
| Pharmacie MORY Sint-Gillis (bij-Brussel) | €349,639 | €131,549 | 28.9% | - |
| PHARMACIE DU MIROIR Jette | €358,930 | €118,986 | 2.4% | - |
| PHARMACIE GILISQUET Schaerbeek | €391,819 | €117,002 | -80.8% | - |
| Pharmacie Marie-Anne TYCHON Liège | €362,681 | €131,572 | 78.6% | - |
| Apotheek Werchter Rotselaar | €402,771 | €129,592 | 52.3% | 1 |
| PHARMACIE DE BOUSSOIT La Louvière | €349,927 | €119,641 | 65.4% | - |
These companies have the same main activity as Mega Pharma: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €350,000 and €403,000, founded between 2010 and 2013.
Official details
Source: KBO- Status
- Active since 10-11-2011Normal situation
- Activity
- Retail sale of pharmaceutical productsNACE 47730
- Joint committee
- 313Pharmacies and pricing offices · annual accounts 2024
- Establishment unit
- 2.270.810.1841080 Molenbeek-Saint-Jean, since 19-12-2017
- Financial year end
- 31 December
- Peppol
- Reachable since 16-07-2026
Annual accounts 2025
- ≈ €390,000estimated
- €370,696▼ 11.7%
- Employeeson 31-12-2025
- 2▼ 33.3%
- Filing
- Filed on 29-07-2026, 2 days before the end of the filing period
Insights on Mega Pharma
Mega Pharma files the micro format. That format states no turnover. The gross margin rose from -€1,146 in 2012 to €130,361 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about Mega Pharma
- What is the company number of Mega Pharma?
- The company number of Mega Pharma is 0840.972.479. The VAT number is the same number with BE in front: BE 0840.972.479.
- Where is Mega Pharma based?
- The registered office is at Leopold II laan 75, 1080 Molenbeek-Saint-Jean.Company details
- What does Mega Pharma do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of Mega Pharma?
- Mega Pharma is a private limited company (BV).
- When was Mega Pharma founded?
- Mega Pharma was founded on 10-11-2011.
- Is Mega Pharma still active?
- Yes, Mega Pharma is an active enterprise in the KBO register.
- How many employees does Mega Pharma have?
- Mega Pharma had an average of 2.9 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does Mega Pharma fall under?
- In its 2024 annual accounts, Mega Pharma states joint committee 313 (Pharmacies and pricing offices).
- What is the turnover of Mega Pharma?
- The turnover in financial year 2025 is ≈ €390,000. This figure is estimated from the gross margin of €130,361 and 31 comparable companies (NACE 477). It probably lies between €280,000 and €740,000.
- Is Mega Pharma profitable?
- In financial year 2025, Mega Pharma made a loss of €30,878.
- Where can I find the annual accounts of Mega Pharma?
- Mega Pharma filed 14 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of Mega Pharma due?
- Mega Pharma must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.